138 related articles for article (PubMed ID: 31225479)
1. Targeting LRH-1/NR5A2 to treat type 1 diabetes mellitus.
Cobo-Vuilleumier N; Lorenzo PI; Gauthier BR
Cell Stress; 2018 May; 2(6):141-143. PubMed ID: 31225479
[TBL] [Abstract][Full Text] [Related]
2. Time for a paradigm shift in treating type 1 diabetes mellitus: coupling inflammation to islet regeneration.
Cobo-Vuilleumier N; Gauthier BR
Metabolism; 2020 Mar; 104():154137. PubMed ID: 31904355
[TBL] [Abstract][Full Text] [Related]
3. LRH-1 agonism favours an immune-islet dialogue which protects against diabetes mellitus.
Cobo-Vuilleumier N; Lorenzo PI; Rodríguez NG; Herrera Gómez IG; Fuente-Martin E; López-Noriega L; Mellado-Gil JM; Romero-Zerbo SY; Baquié M; Lachaud CC; Stifter K; Perdomo G; Bugliani M; De Tata V; Bosco D; Parnaud G; Pozo D; Hmadcha A; Florido JP; Toscano MG; de Haan P; Schoonjans K; Sánchez Palazón L; Marchetti P; Schirmbeck R; Martín-Montalvo A; Meda P; Soria B; Bermúdez-Silva FJ; St-Onge L; Gauthier BR
Nat Commun; 2018 Apr; 9(1):1488. PubMed ID: 29662071
[TBL] [Abstract][Full Text] [Related]
4. Type 1 diabetes pathogenesis - Prevention???
Krishna CS; Srikanta S
Indian J Endocrinol Metab; 2015 Apr; 19(Suppl 1):S58-63. PubMed ID: 25941654
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stem cells derived in vitro transdifferentiated insulin-producing cells: A new approach to treat type 1 diabetes.
Dave S
Adv Biomed Res; 2014; 3():266. PubMed ID: 25625105
[TBL] [Abstract][Full Text] [Related]
7. Original hypothesis: Extracorporeal shockwaves as a homeostatic autoimmune restorative treatment (HART) for Type 1 diabetes mellitus.
Craig K; d'Agostino C; Poratt D; Walker M
Med Hypotheses; 2014 Sep; 83(3):250-3. PubMed ID: 24947195
[TBL] [Abstract][Full Text] [Related]
8. Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.
Fenske RJ; Kimple ME
Exp Biol Med (Maywood); 2018 Mar; 243(6):586-591. PubMed ID: 29504478
[TBL] [Abstract][Full Text] [Related]
9. Islet β-Cell Mass Preservation and Regeneration in Diabetes Mellitus: Four Factors with Potential Therapeutic Interest.
Mellado-Gil JM; Cobo-Vuilleumier N; Gauthier BR
J Transplant; 2012; 2012():230870. PubMed ID: 22919462
[TBL] [Abstract][Full Text] [Related]
10. Lessons on autoimmune diabetes from animal models.
Yang Y; Santamaria P
Clin Sci (Lond); 2006 Jun; 110(6):627-39. PubMed ID: 16689681
[TBL] [Abstract][Full Text] [Related]
11. NR5A2/LRH-1 regulates the PTGS2-PGE
Martin Vázquez E; Cobo-Vuilleumier N; Araujo Legido R; Marín-Cañas S; Nola E; Dorronsoro A; López Bermudo L; Crespo A; Romero-Zerbo SY; García-Fernández M; Martin Montalvo A; Rojas A; Comaills V; Bérmudez-Silva FJ; Gannon M; Martin F; Eizirik D; Lorenzo PI; Gauthier BR
iScience; 2022 May; 25(5):104345. PubMed ID: 35602948
[TBL] [Abstract][Full Text] [Related]
12. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in type 1 diabetes mellitus: current protocols and future perspectives.
Fändrich F; Ungefroren H
Adv Exp Med Biol; 2010; 654():641-65. PubMed ID: 20217518
[TBL] [Abstract][Full Text] [Related]
13. Durable Control of Autoimmune Diabetes in Mice Achieved by Intraperitoneal Transplantation of "Neo-Islets," Three-Dimensional Aggregates of Allogeneic Islet and "Mesenchymal Stem Cells".
Westenfelder C; Gooch A; Hu Z; Ahlstrom J; Zhang P
Stem Cells Transl Med; 2017 Jul; 6(7):1631-1643. PubMed ID: 28467694
[TBL] [Abstract][Full Text] [Related]
14. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice.
Koulmanda M; Bhasin M; Hoffman L; Fan Z; Qipo A; Shi H; Bonner-Weir S; Putheti P; Degauque N; Libermann TA; Auchincloss H; Flier JS; Strom TB
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16242-7. PubMed ID: 18852471
[TBL] [Abstract][Full Text] [Related]
15. Stem cell applications in diabetes.
Noguchi H
J Stem Cells; 2012; 7(4):229-44. PubMed ID: 24196798
[TBL] [Abstract][Full Text] [Related]
16. β-cell regeneration to treat Type 1 diabetes mellitus.
Barra Couri CE; Foss-Freitas MC; Foss MC; Voltarelli JC
Expert Rev Endocrinol Metab; 2008 Jan; 3(1):51-60. PubMed ID: 30743785
[TBL] [Abstract][Full Text] [Related]
17. Human Induced Pluripotent Stem Cells in the Curative Treatment of Diabetes and Potential Impediments Ahead.
Dadheech N; James Shapiro AM
Adv Exp Med Biol; 2019; 1144():25-35. PubMed ID: 30569414
[TBL] [Abstract][Full Text] [Related]
18. Heparanase and Type 1 Diabetes.
Simeonovic CJ; Popp SK; Brown DJ; Li FJ; Lafferty ARA; Freeman C; Parish CR
Adv Exp Med Biol; 2020; 1221():607-630. PubMed ID: 32274728
[TBL] [Abstract][Full Text] [Related]
19. Potential role of TRAIL in the management of autoimmune diabetes mellitus.
Bernardi S; Norcio A; Toffoli B; Zauli G; Secchiero P
Curr Pharm Des; 2012; 18(35):5759-65. PubMed ID: 22726118
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus.
He B; Li X; Yu H; Zhou Z
J Diabetes; 2015 Nov; 7(6):762-73. PubMed ID: 25799887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
